Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: rheuma plus 2/2018

12.03.2018 | Gicht | Pro und Contra

Colchicin zur Behandlung der Gicht

Pro-Statement

verfasst von: OÄ Dr. J. Sautner

Erschienen in: rheuma plus | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Colchicin ist eine pharmakologische Substanz, die bei Gicht sowohl in der Therapie des akuten Anfalls als auch in der Anfallsprophylaxe eingesetzt werden kann. Colchicin ist Bestandteil aller internationalen Empfehlungen zum Gichtmanagement und ist – wenn auch ein schon seit Jahrtausenden bekanntes pflanzliches Heilmittel – aus dem modernen therapeutischen Armamentarium der Gichttherapie nicht weg zu denken. Weitere rheumatologische Einsatzgebiete sind das familiäre Mittelmeerfieber und der Morbus Behcet. Colchicin wird aber auch bei der akuten und rezidivierenden Pericarditis eingesetzt, hat sich in Studien als günstig in der Prävention von Vorhofflimmern herausgestellt und zählt zu den Phytochemikalien, die offensichtlich ein antikanzerogenes Potential haben.
Literatur
1.
Zurück zum Zitat Kuo CR et al (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662 CrossRefPubMed Kuo CR et al (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662 CrossRefPubMed
2.
Zurück zum Zitat Feig DI et al (2008) Uric acid and cardiovascular risk. N Eng J Med 359(17):1811–1821 CrossRef Feig DI et al (2008) Uric acid and cardiovascular risk. N Eng J Med 359(17):1811–1821 CrossRef
3.
Zurück zum Zitat Kuo CF et al (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75(1):210–217 CrossRefPubMed Kuo CF et al (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 75(1):210–217 CrossRefPubMed
4.
Zurück zum Zitat Choi HK et al (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 57(1):109–115 CrossRefPubMed Choi HK et al (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 57(1):109–115 CrossRefPubMed
5.
Zurück zum Zitat Fisher MC et al (2017) The unclosing premature mortality gap in gout; a general population-based study. Ann Rheum Dis 76:1289–1284 CrossRefPubMed Fisher MC et al (2017) The unclosing premature mortality gap in gout; a general population-based study. Ann Rheum Dis 76:1289–1284 CrossRefPubMed
6.
Zurück zum Zitat Kuo CF, Luo SF (2017) Gout: risk of premature death in gout unchanged for years. Nat Rev Rheumatol 13(4):200–201 CrossRefPubMed Kuo CF, Luo SF (2017) Gout: risk of premature death in gout unchanged for years. Nat Rev Rheumatol 13(4):200–201 CrossRefPubMed
7.
Zurück zum Zitat Sautner J (2014) Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations. Z Rheumatol 73(9):836–842 CrossRefPubMed Sautner J (2014) Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations. Z Rheumatol 73(9):836–842 CrossRefPubMed
8.
Zurück zum Zitat Richette P et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42 CrossRefPubMed Richette P et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42 CrossRefPubMed
9.
Zurück zum Zitat Hui M et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology 56:1246 CrossRefPubMed Hui M et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology 56:1246 CrossRefPubMed
10.
Zurück zum Zitat Kiltz U et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76:1765–1770 CrossRef Kiltz U et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76:1765–1770 CrossRef
11.
Zurück zum Zitat Kiltz U et al (2017) Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector: S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF. Z Rheumatol 76(2):118–124 CrossRefPubMed Kiltz U et al (2017) Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector: S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF. Z Rheumatol 76(2):118–124 CrossRefPubMed
12.
Zurück zum Zitat Sivera F et al (2014) Multination evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73(2):328–335 CrossRefPubMed Sivera F et al (2014) Multination evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73(2):328–335 CrossRefPubMed
13.
Zurück zum Zitat Khanna D et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446 CrossRef Khanna D et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446 CrossRef
14.
Zurück zum Zitat Sautner J et al (2014) Austrian 3e-recommendations for diagnosis and management of gout 2013. Wien Klin Wochenschr 126(3–4):79–89 CrossRefPubMed Sautner J et al (2014) Austrian 3e-recommendations for diagnosis and management of gout 2013. Wien Klin Wochenschr 126(3–4):79–89 CrossRefPubMed
17.
Zurück zum Zitat Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068 CrossRefPubMed Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068 CrossRefPubMed
18.
Zurück zum Zitat Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate – lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397 CrossRefPubMed Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate – lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397 CrossRefPubMed
19.
Zurück zum Zitat Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461 CrossRefPubMed Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461 CrossRefPubMed
20.
Zurück zum Zitat Schumacher HR Jr et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540–1548 CrossRefPubMed Schumacher HR Jr et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540–1548 CrossRefPubMed
21.
Zurück zum Zitat Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63 CrossRefPubMedPubMedCentral Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Zemer D et al (1986) Colchicine in the prevention and treatment of the amyloidosis in familial Mediterranean fever. N Eng J Med 314(16):1001–1005 CrossRef Zemer D et al (1986) Colchicine in the prevention and treatment of the amyloidosis in familial Mediterranean fever. N Eng J Med 314(16):1001–1005 CrossRef
24.
Zurück zum Zitat Deftereos S et al (2012) Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 60(18):1790–1796 CrossRefPubMed Deftereos S et al (2012) Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 60(18):1790–1796 CrossRefPubMed
27.
Zurück zum Zitat Nidorf SM et al (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 29(4):404–410 CrossRef Nidorf SM et al (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 29(4):404–410 CrossRef
28.
Zurück zum Zitat Solomon DH et al (2016) Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 75:1674–1679 CrossRefPubMed Solomon DH et al (2016) Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 75:1674–1679 CrossRefPubMed
33.
Zurück zum Zitat Kumar A et al (2017) Potential anticancer role of colchicine – based derivatives: an overview. Anticancer Drugs 28(3):250–262 CrossRefPubMed Kumar A et al (2017) Potential anticancer role of colchicine – based derivatives: an overview. Anticancer Drugs 28(3):250–262 CrossRefPubMed
34.
Zurück zum Zitat Cho JH et al (2017) Anticancer effects of colchicine on hypopharyngeal cancer. Anticancer Res 37(11):6269–6280 PubMed Cho JH et al (2017) Anticancer effects of colchicine on hypopharyngeal cancer. Anticancer Res 37(11):6269–6280 PubMed
Metadaten
Titel
Colchicin zur Behandlung der Gicht
Pro-Statement
verfasst von
OÄ Dr. J. Sautner
Publikationsdatum
12.03.2018
Verlag
Springer Vienna
Schlagwörter
Gicht
Rheumatologie
Erschienen in
rheuma plus / Ausgabe 2/2018
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-018-0174-2